摘要
目的:观察大黄?虫丸联合化疗治疗原发性肝癌的临床疗效。方法:将65例患者随机分为对照组30例,观察组35例,对照组给予CAFI方案进行化疗,观察组在对照组的基础上联合使用大黄?丸进行治疗,治疗2周后观察2组临床疗效及免疫力恢复情况、副反应发生情况和生存率。结果:总有效率观察组为37.14%,对照组为16.67%,2组比较差异有统计学意义(P<0.05)。CD3^+、CD4^+、CD8^+、CD4^+/CD8^+比值及NK细胞水平治疗前后2组组内比较,差异有统计学意义(P<0.05);治疗后2组组间比较差异也有统计学意义(P<0.05)。半年、1年生存率观察组分别为85.71%(30/35)、60.00%(21/35),对照组分别为76.67%(23/30)和43.33%(13/30),2组比较差异均有统计学意义(P<0.05)。0、Ⅲ、Ⅳ级毒副反应发生率2组比较,差异有统计学意义(P<0.05)。结论:大黄?虫丸联合化疗治疗原发性肝癌能够明显提高临床疗效、患者免疫力及生存率,降低副反应发生率。
Objective： To observe clinical effects of DaHuang ZheChong pills joined with chemotherapy in thetreatment for primary liver cancer. Methods： Sixty-five patients were randomized into 30 cases of the control groupand 35 cases of the observation group, the control group were given CAFI regimen while the observation groupDaHuang ZheChong pills on the foundation of chemotherapy, survival rate, the incidence of adverse reaction, therecovery conditions of immunity and clinical effects of both groups were observed after they were treated for twoweeks. Results： Total effective rate of the observation group was 37.14%, higher than 16.67% of the control group,and the difference was statistically significant（P〈0.05）. The difference showed statistical meaning in the compar-isons of the levels of CD3＋, CD4＋, CD8＋, CD4＋/CD8＋ratio and NK cells within two groups before and after treating（P〈0.05）; there was a significant difference in the comparisons between both groups after treating（P〈0.05）.Six-month and one-year survival rates of the observation group were 85.71% （30/35） and 60.00% （21/35）, higherthan 76.67% （23/30） and 43.33% （13/30） of the control group respectively, and the differences had statistical mean-ing（P〈0.05）. The difference had statistical meaning in the comparisons of the incidences of toxic and adverse reac-tions at the stages of 0, Ⅲ and Ⅳ between both groups（P〈0.05）. Conclusion： DaHuang ZheChong pills joined withchemotherapy in the treatment for primary liver cancer could obviously improve clinical effects, enhance body im-munity and survival rate, lower the incidence of side effects.
作者
杨军民
何耀辉
马宝梅
YANG Junmin;HE Yaohui;MA Baomei(Department of Internal Medicine,Linyou County Hospital,Linyou 721599,China;Department of Internal Medicine,Baoji Municipality TCM Hospital)
出处
《西部中医药》
2018年第10期83-85,共3页
Western Journal of Traditional Chinese Medicine
关键词
肝癌
原发性
化疗
大黄[庶虫]虫丸
免疫力
liver cancer
primary
chemotherapy
DaHuang ZheChong pills
immunity
